CRISPR-U™ technology (CRISPR based), developed by Ubigene, is more efficient than general
CRISPR/Cas9 technology in double-strand breaking and homologous recombination. With CRISPR-U™, Ubigene has
successfully edited over 3000 genes on more than 200 types of cell lines.
Objective
To create a Human METTL1 Knockout
model in cell line by CRISPR-U™-mediated genome engineering.
Target gene info
Official symbol
METTL1
Gene id
4234
Organism
Homo sapiens
Gene type
protein-coding
Official full symbol
methyltransferase like 1
Also known as
C12orf1, TRM8, TRMT8, YDL201w
Genomic regions
Chromosome 12
Summary
This gene is similar in sequence to the S. cerevisiae YDL201w gene. The gene product contains a conserved S-adenosylmethionine-binding motif and is inactivated by phosphorylation. Alternative splice variants encoding different protein isoforms have been described for this gene. A pseudogene has been identified on chromosome X.
Strategy Summary
This gene has 0 protein coding transcripts：
Frame-shift
Fragment A
Fragment B
gRNA Detail
Strategy
Project Comprehensive Difficulty Assessment
According to the Red Cotton database: the METTL1 gene is evaluated as high lethality riskin cell line, and the CRISPR gene-editing strategy design is Unknown. Knockout project comprehensive difficulty is thus assessed as Unknown. KO experiment is not recommended.
In all cell lines, there is
3.2% cells with low expression level,
96.7% cells with medium expression level,
0.1% cells with high expression level
of METTL1 gene.
Cell line is not selected, unable to assess the accurate expression level, for reference only.
In all cell lines, there is
56.7% cells with low copy number,
37.3% cells with medium copy number,
5.9% cells with high copy number
of METTL1 gene.
Cell line is not selected, unable to assess the accurate copy number, for reference only.
Ubigene is an international high-technology enterprise focused on gene-editing cells. Our exclusive CRISPR-U™ technology has 10-20 times more efficient editing than traditional methods, easily achieving gene knockout, point mutation, and knock-in. Based on CRISPR-U™ technology, Ubigene has accumulated over 6000 successful gene-editing cases from more than 300 cell lines including iPSC and ESC, and has established a KO Cell Line Bank with 4500+ KO cell lines and Red Cotton™ gRNA Plasmid Bank with 10000+ gRNA plasmids available in stock.
Ubigene focuses on technological innovation and product development, of which EZ-editor™ series products that cover the whole workflow of gene-editing keep improving. Ubigene will move on toward our goal of "Make genome editing easier" and we won't stop!
EZ-editor™ Gene Dependency
EZ-editor™ Gene Expression Level 
EZ-editor™ Gene Copy Number 
